-
Innovation Ranking
NewInnovation Ranking – Alfa Laval AB
Alfa Laval AB (Alfa Laval) is a provider of specialized products and solutions for heat transfer, separation, and fluid handling. Its product portfolio includes centrifuges, pumps and valves, heat exchangers, thermal fluid systems, boilers, decanters, burners, evaporation systems, high speed separators and tank equipment. The company's products optimize the processes such as heating, cooling, separating and transporting of products including oil, water, chemicals, beverages, and foodstuffs. The company caters to energy, paper and pulp, steel, chemicals, food, dairy and beverages,...
-
Innovation Ranking
NewInnovation Ranking – Alfa SAB de CV
Alfa SAB de CV (Alfa) is a diversified company that operates in the petrochemical, refrigerated food, lightweight solutions, telecommunication, and oil and gas sectors. The company develops and manufactures high-technology aluminum components for the power train and body structure of automotive. It produces processed meats, cheese, yogurt and prepared meals. Alfa provides information technologies and communications services. The company explores for hydrocarbons and produces oil and gas. Alfa serves to food, beverages, consumer products, packaging, automotive, energy markets, enterprise and...
-
Product Insights
NewNet Present Value Model: Takeda Pharmaceutical Co Ltd’s Modakafusp Alfa
Empower your strategies with our Net Present Value Model: Takeda Pharmaceutical Co Ltd's Modakafusp Alfa report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s MEDI-7352
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's MEDI-7352 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s Insulin Efsitora Alfa
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Insulin Efsitora Alfa report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Myelofibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Myelofibrosis Drug Details: Ropeginterferon alpha-2b (Besremi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab in Colorectal Cancer Drug Details: Bevacizumab (Avastin) is a recombinant humanized...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Modakafusp Alfa in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Modakafusp Alfa in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Modakafusp Alfa in Metastatic Melanoma Drug Details: TAK-573 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Pemphigus Vulgaris
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Pemphigus Vulgaris report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Pemphigus Vulgaris Drug Details: Efgartigimod alfa-fcab (Vyvgart) is...